Class effects of statins in elderly patients with congestive heart failure: A population-based analysis

• Published in: The American heart journal 2008-02, Vol.155 (2), p.316-323
• Main Authors: Rinfret, Stéphane, MD, MSc, Behlouli, Hassan, PhD, Eisenberg, Mark J., MD, MPH, Humphries, Karin, DSc, Tu, Jack V., MD, PhD, Pilote, Louise, MD, MPH, PhD
• Format: Article
• Language: English
• Subjects: Aged; Atorvastatin Calcium; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular; Cholesterol; Drug therapy; Female; Heart; Heart attacks; Heart Failure - drug therapy; Heart Failure - mortality; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Heptanoic Acids - therapeutic use; Hospitals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Lovastatin - therapeutic use; Male; Medical sciences; Mortality; Pravastatin - therapeutic use; Prescription drug plans; Pyrroles - therapeutic use; Simvastatin - therapeutic use; Statins; Survival Analysis; Treatment Outcome
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2007.09.004

Background Long-term treatment with statins reduces mortality in patients with congestive heart failure (CHF). Whether statin agents exert a class effect is unknown. Methods We analyzed long-term mortality in Canadian patients aged ≥65 years who were discharged from hospital with a diagnosis of CHF from January 1998 to December 2002. Administrative data from Quebec, Ontario, and British Columbia were merged. We compared patients prescribed with atorvastatin, simvastatin, pravastatin, and lovastatin. Results A total of 15 368 patients hospitalized with a diagnosis of CHF fulfilled the inclusion criteria for this study. In this final dataset, 6670 (43.4%) filled a prescription for atorvastatin, 4261 (27.7%) for simvastatin, 3209 (20.9%) for pravastatin, and 1228 (8.0%) for lovastatin. Clinical characteristics and proportion of days covered with a statin prescription were similar across groups. Drug dosages were relatively low, with 82% of patients who received the agent at a dose of ≤20 mg. Although controlling for time-dependent covariates representing current use and dosage, as well as for age, sex, coronary artery disease, and several other comorbidities, treatment with pravastatin (adjusted hazards ratio [HR] 0.94, 95% CI 0.83-1.07), lovastatin (adjusted HR 1.02, 95% CI 0.88-1.17), or simvastatin (adjusted HR 0.92, 95% CI 0.83-1.01) had a similar effectiveness to prevent mortality compared to atorvastatin (reference in this analysis) in this population with CHF. Time-dependent exposure to a statin was highly protective against mortality. Conclusions Statins exert a class effect in patients with CHF, when used at a relatively low dose. The favorable effects appear largely independent of drug dosage.